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SYNOPSIS 
 
The Laser in Glaucoma and Ocular Hypertension trial is a multicentre randomised controlled 
trial investigating the health-related quality of life, clinical and cost-effectiveness of drops vs. 
selective laser trabeculoplasty as a first line treatment.  
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ABSTRACT 
 
Purpose 
The Laser in Glaucoma and Ocular-Hypertension (LiGHT) Trial aims to establish whether 
initial treatment with selective laser trabeculoplasty (SLT) is superior to initial treatment with 
topical medication for Primary Open Angle Glaucoma (POAG) or Ocular Hypertension 
(OHT). 
Design 
The LiGHT Trial is a prospective unmasked, multi-centre, pragmatic, randomised controlled 
trial. 718 previously untreated patients with POAG or OHT were recruited at 6 collaborating 
centres in the United Kingdom between 2012 and 2014. The trial comprises two treatment 
arms: initial SLT followed by conventional medical therapy as required and medical therapy 
without laser therapy. Randomisation was provided online by a web-based randomisation 
service. Participants will be monitored for 3 years, according to routine clinical practice. The 
target intraocular pressure (IOP) was set at baseline according to an algorithm, based on 
disease severity and lifetime risk of loss of vision at recruitment and subsequently adjusted 
on the basis of IOP control, optic disc and visual field. The primary outcome measure is 
Health Related Quality of Life (EQ-5D-5L). Secondary outcomes are treatment pathway cost 
and cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, Glaucoma 
Quality of Life, objective measures of pathway effectiveness, visual function and safety 
profiles and concordance. A single main analysis will be performed at the end of the trial on 
an intention-to-treat basis. 
Conclusions 
The LiGHT Trial is a multicentre, pragmatic, randomised clinical trial that will provide 
valuable data on the relative HRQL, clinical and cost effectiveness of SLT and topical IOP 
lowering medication. 
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INTRODUCTION 
Primary open-angle glaucoma (POAG) is an irreversible optic neuropathy, affecting up to 4% 
of white and 15% of black populations by the age of 801 and a leading cause of blind 
registrations, falls and loss of independence,2 significantly affecting Quality of Life (QoL).3 
IOP is the only modifiable risk factor, the reduction of which is proven to slow down the 
progression of the disease.4 Although the effectiveness of hypotensive drops is irrefutable, 
they come with a number of potential aesthetic, sight threatening and serious systemic side 
effects,5, 6 and may have a negative impact on the success of subsequent surgical 
intervention.7 Medical management of POAG and OHT requires regular monitoring, as well 
as multiple hospital visits.  
Selective laser trabeculoplasty (SLT) involves a painless outpatient application of laser to the 
trabecular meshwork. Economic modelling has predicted that using SLT as a first line 
treatment compared to topical medication will significantly reduce healthcare costs,8 
although this has been refuted by others.9  Research recommendations by NICE and 
Cochrane have identified the need for robust randomised clinical trials (RCT) investigating 
the efficacy and cost-effectiveness of SLT as a first line treatment.10, 11  
This paper describes the design of the Laser in Glaucoma and Ocular Hypertension (LiGHT) 
Trial that compares health-related quality of life (HRQL), cost effectiveness and clinical 
outcomes for patients who start treatment with topical IOP lowering medication (“Medicine-
1st” pathway) to that for patients who are first treated with SLT (“Laser-1st” pathway).  
METHODS 
Study design 
LiGHT is a multicentre RCT unmasked to treatment allocation. The study adheres to the 
tenets of the Declaration of Helsinki and is registered at www.controlled-trials.com 
(registration number ISRCTN32038223).  Ethical approval was granted by the City Road and 
Hampstead Research and Ethics Committee. The trial is monitored by a Trial Management 
Group, a Trial Steering Committee and a Data and Safety Monitoring Committee. 
Eligible patients are randomised on a 1:1 ratio to receive either medical therapy or SLT as 
first line treatment for POAG or OHT. All measurements influencing treatment escalation 
decisions, i.e. IOP, HRT, VF, are made by masked observers (optometrists and/or 
technicians). Patients are monitored for 3 years. Monitoring intervals and treatment 
escalation decisions are guided by clinical decision support software (DSS) implementing a 
defined protocol based on published evidence-based guidelines, while also attempting to 
capture the complexities of clinical practice. Inclusion and exclusion criteria are shown in 
Table 1.  
Inclusion criteria Exclusion criteria 
Newly diagnosed and untreated POAG or 
OHT
a 
with a decision to treat
b 
made by a 
consultant ophthalmologist
c
 
Advanced POAG
d
 
18 years or older Visual acuity worse than 6/36 in a study eye
e
 
Able to provide informed consent Secondary glaucoma
f
 
Able to understand English Angle closure 
  
 Congenital/early childhood glaucoma 
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 Previous treatment for POAG/OHT 
 Contra-indication to SLT 
 Inability to use topical medical therapy 
 Visually significant cataract 
 Active treatment for another ophthalmic 
condition in either eye 
 History of retinal ischaemia, macular oedema 
or diabetic retinopathy 
 Age-related macular degeneration with 
neovascularisation or geographic atrophy 
 Previous intra-ocular surgery
g
 
 Pregnancy or intention to become pregnant 
 Medically unfit for completion of the trial 
 Involvement in another interventional 
research study 
Table 1 Inclusion and exclusion criteria to the LiGHT Trial; a: in one or both eyes (including 
pseudoexfoliation glaucoma) b: under NICE guidelines
11 
c: fellowship-trained glaucoma sub-specialist 
consultant ophthalmologist, , d: VF loss mean deviation worse than -12 dB in the better or -15 dB in 
the worse eye, e: uni-ocular patients were eligible, f: pigment dispersion syndrome, trauma, g: except 
uncomplicated phaco-emulsification at least one year before entering the trial. 
Recruitment 
Consecutive eligible patients were identified at six participating centres from October 2012 
until October 2014 (Appendix 1). Patients who decided to participate were given a baseline 
assessment on a different day and those who declined were asked for a reason for their 
refusal.  
Baseline assessment 
At the baseline assessment, participants underwent visual acuity testing (ETDRS logMAR), 
slit-lamp examination, automated visual field (VF) testing (Humphrey Field Analyser (HFA) 
Mark II SITA standard 24-2), Heidelberg Retina Tomography (HRT) optic disc imaging, IOP 
measurement, gonioscopy, central corneal thickness (CCT) measurement, assessment of 
the optic discs, maculae and fundi. The schedule of examinations is given in Appendix 2. 
The patients also filled in the following questionnaires: EQ-5D 5 level (EQ-5D-5L),12 
Glaucoma Utility Index (GUI),13 Glaucoma Symptom Scale (GSS),14 Glaucoma Quality of 
Life – 15 (GQL-15; a visual function, rather than quality of life, measure)14 and a modified 
version of the ‘Client Service Receipt Inventory’ (CSRI) questionnaire to collect health-
related cost data.15  
Standardisation of disease stratification and individual patient treatment IOP targets 
using a web-based real-time decision support algorithm 
The NICE recommended thresholds were used for defining disease (POAG or OHT) for 
entry into the study, as well as initiating treatment.11 A real-time web-based clinical DSS, 
based on the analysis of HRT, VF and IOP measurements, avoids bias from unmasked 
clinicians. A disease category and stage were defined, using preset objective severity criteria 
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from the Canadian Target IOP Workshop16 with additional central VF loss criteria according 
to Mills et al. 2006.17 Severity stratification (mild, moderate or severe) then determined the 
follow-up intervals and an eye specific 'Treatment Target IOP'.  Target IOP was objectively 
defined based on both percentage reduction from untreated IOP and an absolute value and 
then adjusted during the study according to presence or absence of disease progression 
(Figure 1). The lowest permitted Target was 8 mmHg for POAG and 18 mmHg for OHT†. Not 
all permutations of clinical behaviour could be captured within the DSS, thereforedeviation 
by the treating consultant from DSS advice was permitted; the reason was recorded for 
comparison between treatment arms, e.g. if poor concordance contributed to a failure to 
meet Target IOP rather than drug effectiveness. 
Randomisation and allocation of participants to treatment groups 
Randomisation was undertaken online using a web-based randomisation service, achieving 
full allocation concealment (www.sealedenvelope.co.uk). Stratified randomisation with 
random block sizes was used to randomise in a 1:1 ratio at the level of the patient, with the 
stratification factors of diagnosis and treatment centre. Patients with one or both eyes 
eligible were treated identically.  
Trial arm 1 – Laser-1st pathway 
Standardisation of SLT delivery was achieved by protocol-defined settings and clinical 
endpoint of fine bubble formation at the trabecular meshwork at least 50% of the time 
(Appendix 3). One SLT re-treatment was allowed, provided there was an initial response to 
the treatment. After two SLT treatments the next escalation was medical treatment. 
Significant complications of laser treatment (e.g. severe uveitis, IOP spike greater than 15 
mmHg) or other new medical conditions prevented repetition of SLT.  
Trial arm 2 – Medicine-1st pathway 
Patients on the Medicine-1st pathway or patients that remained uncontrolled on Laser-1st 
pathway were started on single drugs at initiation and with each treatment switch or 
escalation. Drug classes for 1st, 2nd, or 3rd line treatment were defined as per NICE11 and 
European Glaucoma Society (EGS) guidance18 (1st line: prostaglandin analogues, 2nd line: 
beta blockers, 3rd or 4th line: topical carbonic anhydrase inhibitors or alpha-agonists). Fixed 
combination drops were allowed. Systemic carbonic anhydrase inhibitors were only 
permitted as a temporary measure while awaiting surgery and did not influence treatment 
escalation. Maximum medical therapy (MMT) is defined as the most intensive combination of 
drops an individual can reasonably, reliably and safely use and varied between patients. 
MMT is defined as a maximum of 3 drugs and 5 dosages per day for triggering the offer of 
surgery, although MMT may be less for certain patients; more agents could be used for 
patients who decline trabeculectomy. Criteria for failure to meet and to reassess Target IOP 
are shown in Appendix 4.  
Treatment escalation 
To minimise bias for escalating treatment, standardised criteria were used according to a 
protocol following international guidelines by the EGS, American Academy of Ophthalmology 
Preferred Practice Pattern and the South-East Asia Glaucoma Interest Group. Treatment 
was escalated under the following circumstances:  
1. ‘Strong Evidence’ of progression irrespective of IOP 
                                                          
†
 Although CCT has an effect on IOP measurement and risk of progression, the true magnitude of this interaction 
is unknown because of complex non-linear interactions between CCT, ‘true’ IOP and corneal material properties; 
CCT is, therefore, not used in the algorithm for setting Target IOP. Myopia and family history are also not 
included in this algorithm, as data on the effect size of these risk factors on progression rates are weak. 
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2. IOP above Target by more than 4mmHg at a single visit  
3. IOP above Target by less than 4mmHg and ’Less Strong Evidence’ for progression. If 
the IOP is above Target by less 4mmHg with no evidence for progression, then the 
'Treatment Target IOP' is re-evaluated 
The process for escalating treatment is shown in Figure 2.  
Defining disease progression by HRT and Visual Field 
A minimum of 2 reliable baseline VF measurements (based on reliability indices and clinician 
judgement) and 3 follow-up VF were required. ‘Likely VF Progression’ is determined as ≥3 
locations on the HFA GPA were at <0.05 probability for deterioration on 3 consecutive 
occasions. ‘Possible VF Progression’ was determined as ≥3 locations were at <0.05 
probability for deterioration on 2 consecutive occasions. Any treatment escalation triggered 
by worsening visual field loss required senior clinician verification.  
Progression of optic disc damage was defined as a statistically significant rate of neuro-
retinal rim loss exceeding 1% of baseline rim area/year on a minimum of 5 repeat HRT 
images.  
Progression of Glaucoma was defined as: ‘Strong evidence': GPA 'Likely progression' and/or 
HRT rim area >1% per year (p <0.001); ‘Less strong evidence' = GPA 'Possible progression' 
and/or HRT rim area >1% per year (p <0.01). 
Follow-up procedure and timing 
Follow-up intervals were initially set at entry to the study according to NICE guidance11 and 
subsequently adjusted on the basis of IOP control, glaucoma progression or adverse 
reactions. The routine schedule of appointments and assessments for patients are shown in 
Appendices 2 and 5, respectively.  
Adverse events  
Adverse events were reported according to standard operating procedures to achieve 
standardisation across sites and between treatment allocation, with an annual safety report 
to the Research and Ethics Committee.  
Outcome measures 
The primary outcome measure is Health Related Quality of Life (HRQL) using EQ-5D-5L 
utility scores at 3 years, calculated using the EQ-5D-5L descriptive system and value set for 
England (Office of Health Economics).19 Quality-Adjusted Life Years (QALYs) will also be 
calculated over the 36 month period, using the baseline and 6-monthly follow up 
questionnaires and calculating the area under the curve. 
The secondary outcomes are:  
 Treatment pathway health care resource use, cost and cost-effectiveness. Health 
care resource use will be ascertained from the record of treatment episodes and 
additional healthcare contacts from a modified CSRI.15 The cost components will 
include the cost of SLT, number of visits, number and type of medications and 
glaucoma surgeries and clinical tests 
 Glaucoma specific treatment-related quality of life will be measured using the GUI  
 Patient reported disease and treatment related symptoms using the GSS  
 Patient reported visual function using the GQL-15 
 Objective measurements of pathway effectiveness for IOP lowering and visual 
function preservation (e.g. treatment intensity and time taken to  achieve Target IOP, 
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the number of Target IOP revisions, proportion of patients achieving Target after 
each year of treatment, number of patients with confirmed disease deterioration and 
rates of ocular surgery) 
 Objective safety measures for each pathway 
 Concordance,  was assessed by two questions shown to predict the probability of 
non-concordance 20  
 
Sample size calculation 
A difference in EQ-5D-5L utility scores of 0.05 has been considered to be clinically 
meaningful in an MRC-funded trial of glaucoma surgery21, less than the difference between 
mild (0.84±0.17) and moderate (0.68±0.26) visual field loss.22 A study with 305 participants 
in each group would have 90% power to detect, at 5% significance level, a difference in 
means of 0.05, assuming that a common standard deviation of 0.19 and using a two-sided-
test. Allowing for 15% loss to follow-up at 36 months, the total number required for the study 
is 718 (359 in each group). The sample size was calculated using Stata 12 (StataCorp LP, 
Texas, USA).  
Statistical analysis plan 
The statistical analysis has been published elsewhere.23 The analysis will be based on all 
participants as randomised, irrespective of subsequent concordance with allocated 
treatment. The primary outcome will be compared between treatment arms using regression 
methods that adjust for baseline EQ-5D-5L score, IOP and disease laterality. Statistical 
significance will be at 5%. Mixed models will be used to investigate how primary and 
secondary outcomes change over time.  
Discussion 
LiGHT is a multi-centre RCT, unmasked to treatment allocation, designed to compare 
HRQL, clinical- and cost-effectiveness and clinical safety of SLT versus topical IOP lowering 
medication in treatment-naïve patients with newly diagnosed POAG or OHT. This study 
addresses well one of the James Lind Alliance glaucoma research priorities.24 
In the LiGHT Trial concern about possible confounding effects of placebo treatment and 
altered compliance from sham laser require patients to be aware of their treatment 
allocation. Patients’ knowledge of prior medical treatment and/or initial treatment with laser 
may influence subsequent medication-taking behaviour and compliance. Although the 
patients and clinicians are unmasked to the treatment arm, all clinical measures (IOP, VF, 
HRT) are made by masked observers. Moreover, treatment decisions are masked by the 
use of a computerised evidence-based DSS. The potential for bias arising from lack of 
masking patients to treatment allocation will be investigated by comparison of EQ5D and 
GUI in patients who use eye-drops after laser alone with those patients who never received 
laser and with the prior period when laser alone was sufficient.  
 
Very few controlled trials have compared medical to laser treatment in patients with POAG 
or OHT. The LiGHT Trial compares the two treatment pathways in previously untreated 
patients, unlike previously conducted trials.25, 26 The non-randomised trial by Katz et al is the 
only trial to have set a personalised IOP target.26 The Target IOP for LiGHT is eye specific, 
objectively defined and adjusted by the DSS, to avoid bias from unmasked clinicians.  
The LiGHT Trial will provide valuable data on the HRQL, clinical and cost effectiveness of 
SLT and topical IOP lowering medication, with the potential to define the choice of 1st line 
treatment.  
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Figure Legends 
 
Figure 1 Process for target IOP setting. *Disease stratification according to Mills et al. 2006 
31. IOP: Intra-ocular pressure, OHT: Ocular Hypertension, POAG: Primary Open Angle 
Glaucoma, GON: Glaucoma Optic Neuropathy, VF: Visual Field 
Figure 2 Process for escalating treatment in POAG. *On 2 consecutive visits. ** As per 
protocol. ^ Until progression confirmed/refuted. VF progression required 3 follow-up VF 
assessments. Maximal IOP: IOP above which surgery was offered even without progression 
or 35 mmHg for OHT, see text. IOP: Intra-ocular Pressure, MMT: Maximum Medical 
Therapy, VF: Visual Field 
 
 
 
